CervoMed Inc.
corporate_fare Company Profile
CervoMed Inc. (NASDAQ:CRVO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 41 items for CRVO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 9 rated 8 or above. Recent SEC coverage for CRVO spans 4, 10-Q, 8-K, 424B3.
Recent high-impact activity:
- CEO John Alam Buys 100,000 CRVO Shares for $152,621 Near 52-Week Low
- Neflamapimod Shows Exposure-Dependent NfL Reduction at 24 Weeks in nfvPPA
- CervoMed Q3 Loss Narrows to $5.9M but Going Concern Doubt Persists on $19.6M Cash
- CervoMed Publishes Phase 2b DLB Data; Primary Endpoint Missed in Full Population
- CervoMed's Neflamapimod Shows NfL Reduction in nfvPPA Phase 2a
Financial Snapshot
Short Interest & Short Volume
4.65 days to coverFINRA reported short interest of 1,212,655 shares in CRVO as of the October 30, 2026 settlement, a 0.4% increase from the prior period — about 4.7 days to cover at its recent average daily volume. On November 20, 2026, 53.6% of CRVO volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
High riskFiling-implied dilution signals for CRVO, detected from its recent SEC filings · based on capital-structure filings through 2026-07-10.
Registered Direct Offering Finalized · Premium Pricing Achieved
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →